Loading...
XNASBIAFW
Market cap10mUSD
Jan 17, Last price  
0.49USD
1D
-10.91%
1Q
-44.00%
IPO
-76.67%
Name

bioAffinity Technologies Inc

Chart & Performance

D1W1MN
XNAS:BIAFW chart
P/E
—
P/S
3.02
EPS
—
Div Yield, %
%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
+52,627.44%
0004,8032,532,499
Net income
-8m
L-2.66%
-3,307,499-7,268,737-6,326,413-8,154,113-7,937,011
CFO
-6m
L+48.32%
-2,490,196-2,207,639-2,048,978-4,070,845-6,037,806

Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
URL
https://bioaffinitytech.com/
IPO date
Aug 26, 2022
Employees
14
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
2,532
52,627.44%
5
 
Cost of revenue
3,465
4,016
Unusual Expense (Income)
NOPBT
(933)
(4,011)
NOPBT Margin
Operating Taxes
21
2
Tax Rate
NOPAT
(954)
(4,014)
Net income
(7,937)
-2.66%
(8,154)
28.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,027
BB yield
-83.73%
Debt
Debt current
920
252
Long-term debt
2,697
Deferred revenue
Other long-term liabilities
597
Net debt
796
(11,162)
Cash flow
Cash from operating activities
(6,038)
(4,071)
CAPEX
(23)
(220)
Cash from investing activities
(2,209)
(220)
Cash from financing activities
(345)
14,344
FCF
(2,734)
(4,620)
Balance
Cash
2,822
11,414
Long term investments
Excess cash
2,695
11,414
Stockholders' equity
(44,539)
12,145,516
Invested Capital
51,433
(118)
ROIC
ROCE
EV
Common stock shares outstanding
8,748
4,499
Price
1.47
-8.09%
1.60
 
Market cap
12,863
78.70%
7,198
 
EV
13,659
12,178,161
EBITDA
(683)
(4,001)
EV/EBITDA
Interest
37
2,533
Interest/NOPBT